Figure 4.
Progression-Free Survival 1/2 and Overall Survival in different treatment sequences. Horizontal bar charts of combined PFS1 and PFS2 panel (A) and OS panel (B) for ICI given in the first-line followed by tebentafusp in the second-line (n = 31) and tebentafusp in the first-line followed by ICI in the second-line (n = 9) compared with data from the Phase 3 study. ICI = immune checkpoint inhibitor.
